CD8A and atherosclerosis: Current approaches encompass colchicine, monoclonal antibodies targeting pro-inflammatory cytokines like IL-1β and IL-6, low-dose IL-2, CD8+ T cell and B2 cell depletion therapies, and passive and active immunization targeting specific atherosclerosis-associated antigens [42].